ZA201303416B - Methods for enhancing oxygenation of jeopardized tissue - Google Patents
Methods for enhancing oxygenation of jeopardized tissueInfo
- Publication number
- ZA201303416B ZA201303416B ZA2013/03416A ZA201303416A ZA201303416B ZA 201303416 B ZA201303416 B ZA 201303416B ZA 2013/03416 A ZA2013/03416 A ZA 2013/03416A ZA 201303416 A ZA201303416 A ZA 201303416A ZA 201303416 B ZA201303416 B ZA 201303416B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- enhancing oxygenation
- jeopardized tissue
- jeopardized
- tissue
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000006213 oxygenation reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41351910P | 2010-11-15 | 2010-11-15 | |
| PCT/US2011/060747 WO2012068079A1 (en) | 2010-11-15 | 2011-11-15 | Methods for enhancing oxygenation of jeopardized tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201303416B true ZA201303416B (en) | 2017-03-29 |
Family
ID=46084364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/03416A ZA201303416B (en) | 2010-11-15 | 2013-05-10 | Methods for enhancing oxygenation of jeopardized tissue |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20130177524A1 (enExample) |
| EP (1) | EP2640684A4 (enExample) |
| JP (2) | JP5823530B2 (enExample) |
| KR (2) | KR20150124457A (enExample) |
| CN (1) | CN103328427A (enExample) |
| AU (1) | AU2011329088B2 (enExample) |
| BR (1) | BR112013011858A2 (enExample) |
| CA (1) | CA2817542A1 (enExample) |
| CL (1) | CL2013001382A1 (enExample) |
| EA (1) | EA201390720A1 (enExample) |
| IL (1) | IL226285A0 (enExample) |
| MX (1) | MX2013005457A (enExample) |
| NZ (1) | NZ610441A (enExample) |
| PE (1) | PE20140134A1 (enExample) |
| SG (1) | SG190695A1 (enExample) |
| WO (1) | WO2012068079A1 (enExample) |
| ZA (1) | ZA201303416B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103328427A (zh) * | 2010-11-15 | 2013-09-25 | 马斯特治疗公司 | 增强受到危害的组织的氧合的方法 |
| GB201207543D0 (en) * | 2012-05-01 | 2012-06-13 | Haemair Ltd | Treatment of transfusion blood |
| CA2927361A1 (en) * | 2013-10-16 | 2015-04-23 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
| US9403941B2 (en) | 2014-07-07 | 2016-08-02 | Mast Therapeutics, Inc. | Poloxamer composition free of long circulating material and methods for production and uses thereof |
| US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
| WO2016007542A1 (en) | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
| EP3873441A4 (en) | 2018-12-10 | 2022-06-29 | Arshintseva, Elena Valentinovna | A new use of the poloxamer as a pharmacologically active substance |
| EP4401554A4 (en) * | 2021-08-18 | 2025-10-15 | Omniox Inc | H-NOX PROTEINS FOR ORGAN PRESERVATION |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030448A (en) | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
| US5017370A (en) | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
| US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5032394A (en) | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
| US4997644A (en) | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
| US5028599A (en) | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
| US5047236A (en) | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
| US4837014A (en) | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
| US5080894A (en) | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
| US5089260A (en) | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
| US4873083A (en) | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
| US5064643A (en) | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
| US4937070A (en) | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5071649A (en) | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
| US5078995A (en) | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
| US4879109A (en) | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
| US4801452A (en) | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
| US5039520A (en) | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
| US5041288A (en) | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| WO1992016484A1 (en) * | 1991-03-19 | 1992-10-01 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US5605687A (en) | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| US7087369B2 (en) * | 2003-12-17 | 2006-08-08 | The Regents Of The University Of California | Cornea preservation medium |
| EP1804813A4 (en) * | 2004-09-27 | 2011-09-07 | Vical Inc | FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| WO2009023177A1 (en) * | 2007-08-10 | 2009-02-19 | Synthrx, Inc. | Polymer therapy for the treatment of chronic microvascular diseases |
| CN103328427A (zh) * | 2010-11-15 | 2013-09-25 | 马斯特治疗公司 | 增强受到危害的组织的氧合的方法 |
-
2011
- 2011-11-15 CN CN2011800648610A patent/CN103328427A/zh active Pending
- 2011-11-15 WO PCT/US2011/060747 patent/WO2012068079A1/en not_active Ceased
- 2011-11-15 MX MX2013005457A patent/MX2013005457A/es not_active Application Discontinuation
- 2011-11-15 EA EA201390720A patent/EA201390720A1/ru unknown
- 2011-11-15 BR BR112013011858A patent/BR112013011858A2/pt not_active IP Right Cessation
- 2011-11-15 KR KR1020157030550A patent/KR20150124457A/ko not_active Ceased
- 2011-11-15 CA CA2817542A patent/CA2817542A1/en not_active Abandoned
- 2011-11-15 SG SG2013035449A patent/SG190695A1/en unknown
- 2011-11-15 PE PE2013001082A patent/PE20140134A1/es not_active Application Discontinuation
- 2011-11-15 NZ NZ610441A patent/NZ610441A/en unknown
- 2011-11-15 AU AU2011329088A patent/AU2011329088B2/en active Active
- 2011-11-15 JP JP2013538989A patent/JP5823530B2/ja active Active
- 2011-11-15 KR KR1020137015206A patent/KR20130097795A/ko not_active Ceased
- 2011-11-15 EP EP11841387.1A patent/EP2640684A4/en not_active Withdrawn
-
2013
- 2013-03-01 US US13/783,158 patent/US20130177524A1/en not_active Abandoned
- 2013-05-09 IL IL226285A patent/IL226285A0/en unknown
- 2013-05-10 ZA ZA2013/03416A patent/ZA201303416B/en unknown
- 2013-05-15 CL CL2013001382A patent/CL2013001382A1/es unknown
-
2014
- 2014-11-25 US US14/553,913 patent/US20150093368A1/en not_active Abandoned
-
2015
- 2015-10-07 JP JP2015199281A patent/JP2016041714A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150124457A (ko) | 2015-11-05 |
| BR112013011858A2 (pt) | 2017-03-21 |
| CA2817542A1 (en) | 2012-05-24 |
| CL2013001382A1 (es) | 2013-12-20 |
| JP2014506234A (ja) | 2014-03-13 |
| CN103328427A (zh) | 2013-09-25 |
| PE20140134A1 (es) | 2014-02-14 |
| SG190695A1 (en) | 2013-07-31 |
| AU2011329088A1 (en) | 2013-06-27 |
| EP2640684A1 (en) | 2013-09-25 |
| JP5823530B2 (ja) | 2015-11-25 |
| IL226285A0 (en) | 2013-07-31 |
| AU2011329088B2 (en) | 2016-02-25 |
| EA201390720A1 (ru) | 2013-10-30 |
| EP2640684A4 (en) | 2014-04-30 |
| WO2012068079A1 (en) | 2012-05-24 |
| US20130177524A1 (en) | 2013-07-11 |
| US20150093368A1 (en) | 2015-04-02 |
| NZ610441A (en) | 2016-02-26 |
| KR20130097795A (ko) | 2013-09-03 |
| JP2016041714A (ja) | 2016-03-31 |
| MX2013005457A (es) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304280B (en) | Treatment of jak2-mediated conditions | |
| IL220876A0 (en) | Treatment of cardiac conditions | |
| GB201003274D0 (en) | Methods of connecting | |
| ZA201301601B (en) | Treatment of diseases | |
| IL222328A (en) | Tissue microabulation system | |
| EP2552205A4 (en) | PROCESS FOR INCREASING SLEEP QUALITY | |
| GB201018147D0 (en) | Method of treatment | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| ZA201303813B (en) | Methods of treatment using lipid compounds | |
| ZA201303416B (en) | Methods for enhancing oxygenation of jeopardized tissue | |
| IL256026B (en) | Treatment methods | |
| GB201003920D0 (en) | Method of treatment | |
| IL224381B (en) | Application of b-functionalized dihydroxy-chlorins for pdt | |
| IL222360A0 (en) | Method of vaccination | |
| GB201018149D0 (en) | Method of treatment | |
| EP2585103A4 (en) | METHOD OF TREATMENT | |
| GB201020015D0 (en) | Method of treatment | |
| TWM388919U (en) | Structure of endoscope | |
| PL390780A1 (pl) | Sposób biologiczny zwalczania warrozy | |
| HK1189875A (en) | Methods for enhancing oxygenation of jeopardized tissue | |
| TWM402707U (en) | Structure of coffin | |
| TWM402708U (en) | Structure of coffin | |
| EG26997A (en) | Tube for treatment of syrngomylia | |
| GB201000318D0 (en) | Method of treatment | |
| GB201003917D0 (en) | Method of treatment |